Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Immune Checkpoint (PD-1) Inhibitor Combined With Pemetrexed Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC

NCT06132698 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT06132698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06132698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Immune Checkpoint (PD-1) Inhibitor Combined With Pemetrexed Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC
Lead sponsor
West China Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
November 30, 2023
Completion date
June 30, 2026
Enrollment
17 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc associated with leptomeningeal metastases